IHC - ADENOCARCINOMA VS MALIGNANT MESOTHELIOMA (BER-EP4; CEA, CALRETININ, WT-1 )

IHC – Adenocarcinoma vs Malignant Mesothelioma Panel

(BER-EP4, CEA, Calretinin, WT-1)

The IHC Adenocarcinoma vs Malignant Mesothelioma Panel is a highly specialized immunohistochemistry (IHC) diagnostic test used to differentiate between adenocarcinoma and malignant mesothelioma, two cancers that can appear similar under routine microscopic examination.

This advanced diagnostic panel includes four important tumor markers:

• BER-EP4 – Commonly positive in adenocarcinoma
• CEA (Carcinoembryonic Antigen) – Supports adenocarcinoma diagnosis
• Calretinin – Typically positive in mesothelioma
• WT-1 (Wilms Tumor 1) – Supports mesothelial origin confirmation

This panel is essential for accurately distinguishing cancers involving the pleura, lungs, chest cavity, abdominal lining, and other serosal surfaces, where adenocarcinoma and mesothelioma often show overlapping histological features.

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples. Using advanced antibody staining techniques, expert pathologists assess marker expression patterns under the microscope to identify the exact tumor type.

Accurate differentiation is critical because treatment strategies, prognosis, and clinical management differ significantly between adenocarcinoma and malignant mesothelioma.

Benefits of the Test

• Accurately differentiates adenocarcinoma from mesothelioma
• Supports precise cancer classification
• Guides targeted treatment planning
• Helps determine tumor origin
• Improves diagnostic confidence
• Supports oncology decision-making

Why Doctors Recommend This Test

Doctors commonly recommend this panel when:

• Routine biopsy findings are inconclusive
• Pleural or serosal tumors are suspected
• Mesothelioma diagnosis requires confirmation
• Adenocarcinoma origin needs verification
• Cancer treatment depends on exact tumor type
• Specialist oncological evaluation is required
• Histopathology shows overlapping tumor patterns
• Advanced tissue classification is necessary

This test ensures accurate diagnosis for effective cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous histopathology reports
• Relevant imaging and clinical records
• Proper specimen labeling and handling
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for this IHC panel is usually 5–7 working days, depending on tissue processing and staining complexity.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected pleural cancers
• Individuals undergoing mesothelioma evaluation
• Patients with uncertain adenocarcinoma diagnosis
• Individuals requiring advanced tumor classification
• Oncology patients under specialist care
• Patients requiring expert pathology confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert oncopathology specialists ensure highly accurate IHC Adenocarcinoma vs Mesothelioma reports for reliable diagnosis and personalized cancer treatment planning.